About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

NCT00161655·8 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Active plaque psoriasis involving \>10% body surface area and/or minimal screening PASI score 8.
Methotrexate \>7.5 mg/week for the last 3 months

You may not be if

Predominantly guttate, erythrodermic or pustular psoriasis
Other skin conditions than psoriasis

The record

StatusCompleted

PhasePhase 4

Taking part60

StartedApr 2005

UpdatedSep 28, 2009

Conditions

Psoriasis Arthritis, Psoriatic

Where8

Fredriksberg Alle, Copenhagen, Denmark
Gentofte Amtsygehus, Hellerup, Denmark
Helsinki, Helsinki, Finland

Clareo Health | Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis